Related references
Note: Only part of the references are listed.Contact frequency determines outcome of basal insulin initiation trials in type 2 diabetes
S. G. H. A. Swinnen et al.
DIABETOLOGIA (2009)
Differential effects of rosiglitazone and insulin glargine on inflammatory markers, glycemic control, and lipids in type 2 diabetes
L. Raymond Reynolds et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2007)
Impact of medication therapy discontinuation on mortality after myocardial infarction
P. Michael Ho et al.
ARCHIVES OF INTERNAL MEDICINE (2006)
Triple therapy in type 2 diabetes - Insulin glargine or rosiglitazone added to combmiation therapy of sulfonylurea plus metformin in insulin-naive patients
J Rosenstock et al.
DIABETES CARE (2006)
Long-term glycaemic efficacy and weight changes associated with thiazolidinediones when added at an advanced stage of type 2 diabetes
DSH Bell et al.
DIABETES OBESITY & METABOLISM (2006)
Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: Results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study
VL Roberts et al.
CLINICAL THERAPEUTICS (2005)
Adherence with pharmacotherapy for type 2 diabetes: A retrospective cohort study of adults with employer-sponsored health insurance
RP Hertz et al.
CLINICAL THERAPEUTICS (2005)
Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: A randomized, double-blind trial
GE Dailey et al.
AMERICAN JOURNAL OF MEDICINE (2004)
Effect of rosiglitazone versus insulin on the pancreatic β-cell function of subjects with type 2 diabetes
F Ovalle et al.
DIABETES CARE (2004)
Share Paper
